Suggested remit: To appraise the clinical and cost effectiveness of daprodustat within its marketing authorisation for treating anaemia in adults with chronic kidney disease.
The company who makes daprodustat have informed NICE that they will not pursue a license for daprodustat from the UK MHRA. This appraisal will therefore be suspended.
 
Status Suspended
Technology type Medicine
Decision Selected
Process TA
ID number 3987

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors GlaxoSmithKline (Jesduvroq,
  daprodustat)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Polycystic Kidney Disease Charity
Professional groups Anaemia Nurse Specialist Association
  Royal College of Physicians
  UK Kidney Association
Assessment group Centre for Reviews and Dissemination and Centre for Health Economics, University of York
Comparator companies Amgen (darbepoetin alfa) (no CA&U signed, not participating)
  Pfizer (epoetin zeta) (no CA&U signed, not participating)
  Janssen (epoetin alfa) (no CA&U signed, not participating)
  Roche (epoetin beta, methoxy polyethylene glycol-epoetin beta) (no CA&U signed, not participating)
  Astellas Pharma Ltd (roxadustat) (CA&U signed, participating)
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
09 October 2023 Suspended. The company who makes daprodustat have informed NICE that they will not pursue a license for daprodustat from the UK MHRA. This appraisal will therefore be suspended.
22 August 2022 The company, GlaxoSmithKline, has been in touch with NICE to request a delay to the submission. As a consequence, the appraisal committee discussion originally scheduled for 8 February 2023 has been cancelled. A new Committee meeting date has been scheduled for 5 April 2023. The deadline for evidence submission is now 5pm on 6 October 2022 and we anticipate that technical engagement will be in mid-January 2023. Further updates will be available in due course.
15 June 2022 Invitation to participate
28 January 2022 - 25 February 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 November 2021 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual